Heterocyclic Compounds

Matches 351 - 400 out of 944	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/1988/008424A1	PHARMACEUTICALLY ACTIVE AMINES The aromatic amines (I), alkyl amines (II), bicyclic amines (III), cycloalkyl amines (IV), aromatic bicyclic amines (V), hydroquinone amines (VI), quinone amines (VII), amino-ethers (VIII) and bicyclic amino ethers (IX) are useful as pha...
WO/1987/006226A2	AZACYCLOALKANE DERIVATIVES, ABSORPTION PROMOTERS CONTAINING THE DERIVATIVES AS THE EFFECTIVE INGREDIENT AND EXTERNAL PREPARATIONS CONTAINING THE ABSORPTION PROMOTERS An azacycloalkane derivative useful for promoting the absorption of a medicine, an absorption promoting agent comprising at least one of the azacycloalkane derivatives as the effective ingredient for promoting the absorption and an exter...
WO/1987/005898A2	USE OF MALONIC ACID DERIVATIVE COMPOUNDS FOR RETARDING PLANT GROWTH Method for retarding plant growth by applying to the plant an effective amount of a malonic acid derivative compound. This invention also relates to novel malonic acid derivative compounds and processes for the preparation thereof.
WO/1986/000617A1	CONDENSED 7-MEMBERED RING COMPOUNDS AND PROCESS FOR THEIR PREPARATION Novel condensed 7-membered ring compounds represented by formula (I), (wherein R1 and R2 each represents hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy or, when taken together, they represent tri- or tetramethylene, R3 r...
WO/1985/005104A1	FUSED 7-MEMBERED RING COMPOUNDS AND PROCESS FOR THEIR PREPARATION Novel fused 7-membered ring compounds of formula (I), wherein R1 and R2 each represent H, halogen, CF3, lower alkyl, lower alkoxy or R1 and R2 are combined together to represent tri- or tetra-methylene, R3 represents H or optionally subs...
WO/1985/004582A1	NOVEL DOPAMINE AGONISTS Compounds of formula (I), wherein: R1 is H, OH, -OCH3, -CH2OH, -NH2, -NHCH3, -NHCH2CH3, -N(CH3)2, -N(CH2CH3)2, formulas (II), (III), halogen, or formula (IV), wherein R2 is H, -CH3, or formula (V), wherein R3 is phenyl, benzyl, or 1-4 ca...
WO/1985/000810A1	FUSED 7-MEMBERED RING COMPOUNDS AND PROCESS FOR THEIR PREPARATION Novel fused 7-membered ring compounds represented by the general formula (I), wherein R1 and R2 each represent hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy or, when taken together, R1 and R2 represent tri- or tetra-met...
WO/1984/002704A1	TETRACYCLIC COMPOUNDS Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein: X is CH2, O, S, or NR where R is C1-4 alkyl; R1 and R2 are independently selected from hydrogen, hydroxy, C1-4 alkyl, C1-4 alkoxy, halogen or CF3; R3 is C1-7...
WO1984002704A2	TETRACYCLIC COMPOUNDS Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein: X is CH2, O, S, or NR where R is C1-4 alkyl; R1 and R2 are independently selected from hydrogen, hydroxy, C1-4 alkyl, C1-4 alkoxy, halogen or CF3; R3 is C1-7...
WO/1982/002199A1	TRICYCLIC COMPOUNDS New dibenzoxazonine, dibenz-oxazecine or dibenzo-oxaazacycloundecane derivatives and corresponding thia- and aza derivatives thereof, of the general formula I: (FORMULA) or a pharmaceutically acceptable acid addition salt or nitrogen oxi...
WO/1982/002046A1	METHOD OF PREPARATION OF DELTA2 N-HETEROCYCLES Method of preparation of (Alpha)2 N-heterocycles having the general formula I (FORMULA) wherein v is an integer from 1 to 4, R1 represents (if v = 1) hydrogen, one of the following residues: alkyl with 1 to 19 carbon atoms, aralkyl with ...
WO/1980/000838A1	NOVEL 1,4-CYCLO-ALKANO-OXAZEPINES,THEIR PROCESS OF MANUFACTURE,PHARMACEUTICALS CONTAINING THEM AND THEIR UTILISATION Novel 1,4-cyclo-oxazepines of general formula: (FORMULA) in which R1 represents an hydrogen atom; an hydroxyl, alkoxy or acyloxy group having 1 to 4 atoms of carbon, R2 represents a hydrocarbon part having 1 to 3 atoms of carbons, n repr...
JP2024511752A	Macrocycles as CFTR modulators The present invention is based on Ar1, Ar2,R1,R2,R3,R4Macrocyclic compounds of formula (I), in which X is as described in the specification, their manufacture, pharmaceutically acceptable salts thereof and their use as medicaments; The p...
JP2024509760A	APOL1 inhibitor and how to use it As used herein, formula (A'): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein1,X2,X3,X4,Ra,Rb,Rc, L, Q, and Y are as defined herein. Also provided are methods of inhibiting AP...
JP7441947B2	Processes and intermediates for preparing MCL1 inhibitors The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.
JP2024505715A	Fused ring derivatives containing 1,4-oxazepanes The present invention relates to a series of fused ring derivatives containing 1,4-oxazepane and a method for producing the same, and specifically relates to a compound represented by formula (II) and a pharmaceutically acceptable salt t...
JP2023551488A	Small molecule inhibitors of cathepsin C and their pharmaceutical uses The present disclosure relates to small molecule inhibitors of cathepsin C and their pharmaceutical uses. Specifically, provided in this disclosure are amidonitrile compounds represented by Formula VI, pharmaceutical compositions contain...
JP2023550612A	Methods and intermediates for preparing macrocyclic MCL1 inhibitors The invention particularly relates to methods and intermediates for the synthesis of Compound 1, which inhibits MCL1 and is useful in the treatment of cancer.
JP7381543B2	Compounds, compositions and methods The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
JP2023547770A	Compounds and compositions as modulators of TLR signaling The present disclosure provides compounds, pharmaceutical compositions comprising such compounds, and methods or treatments for the treatment of inflammatory diseases and certain neurological disorders associated with inflammatory signal...
JP2023158646A	COMPOSITION AND LIGHT-EMITTING DEVICE USING THEM To provide a composition capable of reducing a driving voltage of a light-emitting device, and provide a light-emitting device using the composition.A composition contains a compound expressed by a formula (FH); and a high molecular comp...
JP2023156479A	(2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS To provide: compounds being inhibitors of dipeptidyl peptidase 1 (DPP1) activity; their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (C...
JP2023540661A	Methods and compositions for targeting Tregs using CCR8 inhibitors The present invention provides compounds of formula (I) as CCR8 inhibitors, which can be used to treat or prevent cancer using CCR8 inhibitors that target tumor-specific regulatory T cells. can be done. Formula (I): [Selection diagram] None
JP2023540083A	Chiralization of diols by nucleophilic aromatic substitution Mcl-1 inhibitor, and the compound Y (variable R1Provided herein are methods for synthesizing intermediates such as (as defined herein). In particular, provided herein are methods of synthesizing Compound A1 and its salts or solvates, Com...
JP2023539101A	Nitrile derivatives acting as inhibitors of dipeptidyl peptidase 1 and their uses Provided are nitrile derivative compounds represented by formula (I), stereoisomers, deuterated products, co-crystals, solvates or pharmaceutically acceptable salts thereof, wherein each group is defined as defined herein. As defined in ...
JP2023126636A	PROCESSES AND INTERMEDIATES FOR PREPARING MCL1 INHIBITORS To provide methods for treating diseases.The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates. The present disclosure relates to methods and intermediates for the synthesis...
JP7339677B2	Fluorosulfonyl-containing compounds, intermediates, methods of preparation and uses thereof Disclosed in the present invention were a fluorosulfonyl-containing compound, an intermediate thereof, a preparation method therefor and use thereof. The fluorosulfonyl-containing compound disclosed in the present invention comprises a c...
JP7336563B2	(2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide as a dipeptidyl peptidase 1 inhibitor The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxam ide compounds (including pharmaceutically acceptable salts thereof),that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their util...
JP2023535957A	substituted haloalkylsulfonanilide herbicides Disclosed are compounds of Formula 1, stereoisomers, N-oxides, and salts thereof, [Chemical 1] where G is CONR5R.6or [Chemical 2] is selected from R.1~R18, Rfand G are as defined in this disclosure. Also disclosed is a composition contai...
JP2023527961A	Antagonist of gpr39 protein Novel compounds have been disclosed that act as antagonists to the human GPR39 protein. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using antagonists in t...
JP2023527161A	P38 alpha mitogen-activated protein kinase inhibitor Disclosed herein are p38α mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and methods of treatment using p38α mitogen-activated protein kinase inhibitors. [Selection figure] None
JP2023526235A	Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein The present disclosure provides crystalline forms of the compound of Formula I: [Chemical 1] and its pharmaceutically acceptable salts. Also described are pharmaceutical compositions containing compounds of Formula I, and methods for the...
JP7294681B2	p-diaminobenzene derivatives as potassium channel modulators, their preparation and their use in medicine The present invention relates to a p-phenylenediamine derivative as a potassium channel regulator and a preparation method and medical application thereof. In particular, disclosed is a compound represented by general formula A or a phar...
JP2023524261A	Synthesis of vinyl alcohol intermediates Provided herein are processes for synthesizing intermediates useful for preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound (E), wherein R1are described herein. Compound (E) can be useful fo...
JP2023524264A	Ring-closure synthesis of macrocyclic Mcl-1 inhibitor intermediates Methods for synthesizing Mcl-1 inhibitors and intermediates such as compound F (variable PG is as defined herein) that can be used to prepare it are described herein. provided. In particular, methods are provided herein for synthesizing ...
JP2023524263A	Synthesis of vinyl-protected alcohol intermediates Provided herein are methods for synthesizing intermediates useful for the preparation of Mcl-1 inhibitors. In particular, methods are provided herein for synthesizing compound D, OPG and R1are described herein. Compound D may be useful i...
JP2023522058A	Benzonitric heterocyclic compound and its preparation and use The present invention discloses benzonitric heterocyclic compounds, methods of making and uses thereof. The present invention provides benzodiazepines of formula I, which can be used as histone deacetylase inhibitors, have selective inhi...
JP7241825B2	Kinase inhibitors and uses thereof The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.
JP2023508997A	Chemical compounds targeting the eye and their use in the treatment of eye diseases The present invention relates to chemical compound C, which is a derivative of norbixin and has ocular tropism, particularly in the context of changes in the retinal pigment epithelium, more particularly in the context of age-related mac...
JP7221202B2	α, β unsaturated amide compounds An object of the present invention is to provide an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The α,β-unsaturated amide compound represented by t...
JP2023501000A	3-(4-(11H-dibenzo[b,e][1,4]azepin-6-yl)piperazin-1-yl)- as H1 and 5-HT2A receptor modulators for the treatment of sleep disorders Propanoic acid derivatives and 3-(4-(dibenzo[b,f][1,4]oxazepine/thiazepine/diazepin-11-yl)piperazin-1-yl)-propa noic acid derivatives The present disclosure provides the 3-(4-(11H-dibenzo[b,e][1,4] Azepin-6-yl)piperazin-1-yl)-propanoic acid derivative, 3-(4-(dibenzo[b,f][1,4]oxazepin-11-yl)piperazin-1-yl)-propan oic acid derivative , 3-(4-(dibenzo[b,f][1,4]thiazepin-11...
JP2023500734A	MCL1 inhibitor The present disclosure relates generally to compounds of formula (I) and pharmaceutical compositions that can be used in methods of treating cancer.
JP2023002643A	HETEROCYCLIC INHIBITORS OF CBP/EP300, AND USES THEREOF IN TREATMENT OF CANCER To provide heterocyclic inhibitors of CBP/EP300, and uses thereof in treatment of cancer.The present invention relates to compounds of formulas (I) and (II) and salts thereof and to compositions and uses thereof. The compounds are useful...
JP7160688B2	Heterocyclic inhibitors of CBP/EP300 and their use in treating cancer The present divisional application relates to compounds of formula (II) or salts thereof, pharmaceutical compositions comprising them, and their medical uses. The compounds are inhibitors of CBP and/or EP300 useful for the treatment of v...
JP2022543106A	HDAC6 inhibitors and their uses Provided herein are compounds that inhibit HDAC6, a protein whose activity is associated with various diseases (eg, cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and dis...
JP2022141920A	COMPOUNDS USEFUL FOR TREATING MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI INFECTION To provide compounds that are useful in treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).The invention provides a compound represented by a formula (I) or a stereoisomer, a pharma...
JP7082445B2	Compounds for treating bovine or porcine respiratory disease The present invention provides compounds for use in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).
JP7064512B2	Kinase inhibitors and their use The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.
JP2022064180A	HETEROCYCLIC COMPOUND To provide a heterocyclic compound with orexin type 2 receptor agonist activity.A compound represented by formula (I), where each symbol is as described in the specification, or a salt thereof has orexin type 2 receptor agonist activity ...
JP2022507879A	Compound In the present invention, the formula (Ia) (in the formula, the XY group is -NHSO2-Or-SO2NH-is; R1Is H or alkyl; R2Is selected from COOH and tetrazolyl groups; R3Is selected from H, Cl and alkyl; R4Is selected from H, Cl and F; R5H, alky...

Matches 351 - 400 out of 944	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >